Breast cancer survivors must remain vigilant for recurrence signs, which can manifest locally, regionally, or distantly. New ...

Regeneron announced the FDA’s approval of two indications of Eylea HD, including an 8mg injection for patients with macular ...

Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an in situ personalized combination ...

Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology ...

– Breast surgery seems to help control cancer in the breast. It could also improve life expectancy for some women.

The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.

This study presents a case report on pain management and comfort care practices for a 52-year-old male patient with advanced osteosarcoma recurrence and systemic metastasis. The patient presented with ...

Dervis, A. (2025) Curative Outcome of Osteosarcoma with Associated Pleural Effusion: A Case Report —Bone Tumor with Pleural ...

NEW YORK – Radiopharm Theranostics on Tuesday said it was cleared by Australian regulators to begin a Phase I trial of its KLK3-targeting radiotherapeutic, RAD 402, for the treatment of metastatic or ...

RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinityTb-161 antitumor activity driven by the dual emission ...

Radiopharm Theranostics (ASX: RAD) has received Bellberry human research ethics committee approval in Australia for a Phase 1 ...